Table 3 Adverse events following vaccination in patients with IMIDs and healthy controls
From: COVID-19 vaccination of patients with chronic immune-mediated inflammatory disease
CoronaVac vaccine | P | ZF2001 vaccine | P | |||
|---|---|---|---|---|---|---|
IMID group | Control group | IMID group | Control group | |||
(n = 123) | (n = 122) | (n = 35) | (n = 31) | |||
Adverse events, n (%) | 24 (19.5) | 62 (50.8) | 0.000 | 5 (14.3) | 6 (19.4) | 0.581 |
Local reactions, n (%) | 22 (17.9) | 53 (43.4) | 0.000 | 4 (11.4) | 5 (16.1) | 0.579 |
Pain | 18 (14.6) | 45 (36.9) | 0.000 | 4 (11.4) | 9 (29) | 0.073 |
Swelling | 5 (4. 1) | 7 (5.7) | 0.544 | 2 (5.7) | 3 (9.7) | 0.544 |
Erythema | 5 (4.1) | 6 (4.9) | 0.747 | 0 | 1 (3.2) | 0.284 |
Induration | 3 (2.4) | 4 (3.3) | 0.693 | 1 (2.9) | 0 | 0.343 |
Systemic reactions, n (%) | 2 (1.6) | 9 (7.4) | 0.030 | 1 (2.9) | 1 (3.2) | 0.931 |
Myalgia | 1 (0.8) | 2 (1.6) | 0.557 | 0 | 1 (3.2) | 0.284 |
Fatigue | 2 (1.6) | 5 (4.1) | 0.245 | 1 (3.2) | 1 (3.2) | 0.931 |
Fever | 0 | 1 (0.8) | 0.314 | 0 | 0 | |
Headache | 1 (0.8) | 4 (3.3) | 0.172 | 0 | 0 | |
Shivering | 0 | 0 | 0 | 0 | ||